129Xe MRI Cardiopulmonary

Launched by BASTIAAN DRIEHUYS · Sep 8, 2023

Keywords

ClinConnect Summary

This clinical trial, called the 129Xe MRI Cardiopulmonary study, is looking to understand how certain lung and heart conditions change over time by using a special MRI technique that involves a gas called xenon. The main goal is to identify three important markers that can provide insights about patients with conditions like interstitial lung disease, chronic thromboembolic pulmonary hypertension, and other related issues such as anemia and difficulty breathing. The study is currently recruiting participants aged 18 and older, including healthy volunteers and patients who are scheduled for blood transfusions or oxygen treatments.

To take part in the trial, participants must be able to give informed consent and meet specific health criteria. For example, healthy volunteers should not have any lung diseases or a significant smoking history, while patients with conditions like interstitial lung disease or pulmonary embolism will be included if they meet certain medical requirements. Participants can expect to undergo MRI scans to help researchers gather valuable information about their conditions. It's important to note that people with certain health issues, such as severe respiratory problems or recent infections, may not be eligible for the study. Overall, this trial aims to improve our understanding of these serious health conditions and how they can be managed.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for Healthy Volunteers:
• • (Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial)
• • 1. Outpatients of either gender, age \> 18
• • 2. Willing and able to give informed consent and adhere to visit/protocol (Consent must be given before any study procedures are performed.)
• • 3. Subject has no diagnosed pulmonary conditions
• • 4. Subject has not smoked in the previous 5 years
• • 5. Smoking history, if any, is less than or equal to 5 pack-years
• • 6. No history of using other inhaled products more than 1/week for \> 1 year
• Inclusion Criteria for Transfusion and Phlebotomy Patients:
• • 1. In-patient or outpatients of either sex, age \> 18
• • 2. Willing and able to give informed consent and adhere to visit/protocol
• And one of the following:
• • 1. Patients who are scheduled to receive a red cell transfusion for anemia.
• • 2. Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis or polycythemia
• • 3. Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer inclusion criteria noted above)
• Inclusion Criteria for Oxygen Administration Patients:
• • 1. In-patient or outpatients of either sex, age \> 18
• • 2. Willing and able to give informed consent and adhere to visit/protocol
• And one of the following categories (ILD, Dyspnea, CTEPH, or Healthy):
• • 1. Interstitial Lung Disease or Dyspnea
• • Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea
• • OR
• • 2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
• • Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation
• • Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans
• • OR
• • 3. Healthy Volunteer (criteria noted above)
• Inclusion Criteria for Acute or Chronic Pulmonary Embolism Patients:
• • 1. In-patient or outpatients of either sex, age \> 18
• • 2. Willing and able to give informed consent and adhere to visit/protocol
• • And one of the following categories (Acute or Chronic)
• • 1. Acute Pulmonary Embolism
• • Patients presenting with acute PE 24-48hrs post-admission
• • Willing to return after 3-6 months of anti-coagulation therapy
• • OR
• • 2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
• • Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation
• • Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans
• Exclusion Criteria for All subjects:
• Subjects presenting with any of the following will not be included in the trial:
• • 1. MRI is contraindicated based on responses to MRI screening questionnaire
• • 2. Subject is pregnant or lactating
• • 3. Resting O2 saturation \<90% with maximum supplemental O2 delivered by nasal canula
• • 4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI
• • 5. Subject has history of any known ventricular cardiac arrhythmia
• • 6. Subject has history of cardiac arrest within the last year
• • 7. Subject does not fit into 129Xe vest coil used for MRI
• • 8. Subject cannot hold his/her breath for 10 seconds
• • 9. Subject deemed unlikely to be able to comply with instructions during imaging
• • 10. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements